Evidence map›Paper›PMID 37450336›Full record

ArticleAnnals of medicine2023

Characteristic analysis of early gastric cancer after

Xinyuan Liu, Xinyu Wang, Tao Mao, Xiaoyan Yin, Zhi Wei, Jindong Fu, Jie Wu, Xiaoyu Li

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Xinyuan LiuDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
Xinyu WangDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
Tao MaoDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
Xiaoyan YinDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
Zhi WeiDepartment of Gastroenterology, Shandong Second Provinical General Hospital, Jinan, P.R. China.
Jindong FuDepartment of Gastroenterology, People's Hospital of Rizhao, Rizhao, P.R. China.
Jie WuDepartment of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
Xiaoyu LiDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
Affiliated Hospital of Qingdao University · CNQingdao University · CNPeople’s Hospital of Rizhao · CNSecond Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsA total of 81 patients of EGC after

resultsThere were more patients in the Hp-eradicated group who received proton pump inhibitor (PPI) for >1 year compared to the control group (

conclusionOur multicenter study revealed that EGC after

Indexed as

Helicobacter InfectionsHelicobacter pyloriStomach NeoplasmsAnti-Bacterial AgentsAtrophyHumansKi-67 AntigenPropensity ScoreProton Pump InhibitorsRetrospective StudiesAnti-Bacterial AgentsKi-67 AntigenProton Pump InhibitorsEGC after H. pylori eradicationendoscopic characteristicsH. pylori infection-related EGCpathological characteristicsretrospective study

Identifiers

PMID37450336
PMCPMC10351464
OpenAlexW4384338498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.